A landscape of checkpoint blockade resistance in cancer : underlying mechanisms and current strategies to overcome resistance
The discovery of immune checkpoints and the development of immune checkpoint inhibitors (ICI) have achieved a durable response in advanced-stage cancer patients. However, there is still a high proportion of patients who do not benefit from ICI therapy due to a lack of response when first treated (primary resistance) or detection of disease progression months after objective response is observed (acquired resistance). Here, we review the current FDA-approved ICI for the treatment of certain solid malignancies, evaluate the contrasting responses to checkpoint blockade in different cancer types, explore the known mechanisms associated with checkpoint blockade resistance (CBR), and assess current strategies in the field that seek to overcome these mechanisms. In order to improve current therapies and develop new ones, the immunotherapy field still has an unmet need in identifying other molecules that act as immune checkpoints, and uncovering other mechanisms that promote CBR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Cancer biology & therapy - 25(2024), 1 vom: 31. März, Seite 2308097 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Santiago-Sánchez, Ginette S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Checkpoint blockade resistance |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/15384047.2024.2308097 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367955105 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367955105 | ||
| 003 | DE-627 | ||
| 005 | 20240312233713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15384047.2024.2308097 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM367955105 | ||
| 035 | |a (NLM)38306161 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Santiago-Sánchez, Ginette S |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A landscape of checkpoint blockade resistance in cancer |b underlying mechanisms and current strategies to overcome resistance |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The discovery of immune checkpoints and the development of immune checkpoint inhibitors (ICI) have achieved a durable response in advanced-stage cancer patients. However, there is still a high proportion of patients who do not benefit from ICI therapy due to a lack of response when first treated (primary resistance) or detection of disease progression months after objective response is observed (acquired resistance). Here, we review the current FDA-approved ICI for the treatment of certain solid malignancies, evaluate the contrasting responses to checkpoint blockade in different cancer types, explore the known mechanisms associated with checkpoint blockade resistance (CBR), and assess current strategies in the field that seek to overcome these mechanisms. In order to improve current therapies and develop new ones, the immunotherapy field still has an unmet need in identifying other molecules that act as immune checkpoints, and uncovering other mechanisms that promote CBR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Immune checkpoint inhibitors (ICI) | |
| 650 | 4 | |a checkpoint blockade resistance | |
| 650 | 4 | |a checkpoint blockade resistance mechanisms | |
| 650 | 4 | |a immune checkpoint blockade | |
| 650 | 4 | |a immunotherapy resistance | |
| 700 | 1 | |a Fabian, Kellsye P |e verfasserin |4 aut | |
| 700 | 1 | |a Hodge, James W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer biology & therapy |d 2002 |g 25(2024), 1 vom: 31. März, Seite 2308097 |w (DE-627)NLM12031438X |x 1555-8576 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:31 |g month:03 |g pages:2308097 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15384047.2024.2308097 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 1 |b 31 |c 03 |h 2308097 | ||